APO Research
Talk to an analyst

APO RESEARCH · REPORT

Spinal Muscular Atrophy Medicine

Compare research editions
View pricing & licenses

Selected research

Industry Research

Spinal Muscular Atrophy Medicine Industry Research Report 2026

26 December 2025131 pages

Choose your research edition.

Industry ResearchSpinal Muscular Atrophy Medicine Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Spinal Muscular Atrophy Medicine Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Spinal Muscular Atrophy Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Spinal Muscular Atrophy Medicine Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Spinal Muscular Atrophy Medicine Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Spinal Muscular Atrophy Medicine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Spinal Muscular Atrophy Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Spinal Muscular Atrophy Medicine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Spinal Muscular Atrophy Medicine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Spinal Muscular Atrophy Medicine include Novartis AG, Astellas Pharma Inc., WAVE Life Sciences Ltd., Vybion, Inc., Voyager Therapeutics, Inc., Sarepta Therapeutics, Inc., Neurotune AG, Neurodyn Inc. and Longevity Biotech, Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Spinal Muscular Atrophy Medicine market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Spinal Muscular Atrophy Medicine Market by Company

Novartis AG

Astellas Pharma Inc.

WAVE Life Sciences Ltd.

Vybion, Inc.

Voyager Therapeutics, Inc.

Sarepta Therapeutics, Inc.

Neurotune AG

Neurodyn Inc.

Longevity Biotech, Inc

Ionis Pharmaceuticals, Inc.

GMP-Orphan SAS

Genzyme Corporation

Genethon

F. Hoffmann-La Roche Ltd.

Cytokinetics, Inc. 24

Bioblast Pharma Ltd.

AveXis, Inc.

Spinal Muscular Atrophy Medicine Segment by Type

LMI-070

ND-602

NT-1654

NXD-30001

Nusinersen

Others

Spinal Muscular Atrophy Medicine Segment by Application

Hospital

Clinic

Others

Spinal Muscular Atrophy Medicine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Spinal Muscular Atrophy Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Spinal Muscular Atrophy Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Spinal Muscular Atrophy Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Spinal Muscular Atrophy Medicine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Spinal Muscular Atrophy Medicine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Spinal Muscular Atrophy Medicine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Spinal Muscular Atrophy Medicine Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Spinal Muscular Atrophy Medicine Sales (W Units) of Manufacturers (2021-2026) Table 7. Global Spinal Muscular Atrophy Medicine Sales Market Share by Manufacturers (2021-2026) Table 8. Global Spinal Muscular Atrophy Medicine Revenue of Manufacturers (2021-2026) Table 9. Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Spinal Muscular Atrophy Medicine Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Spinal Muscular Atrophy Medicine Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Spinal Muscular Atrophy Medicine, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Spinal Muscular Atrophy Medicine, Product Type & Application Table 14. Global Spinal Muscular Atrophy Medicine Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Spinal Muscular Atrophy Medicine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Novartis AG Company Information Table 19. Novartis AG Business Overview Table 20. Novartis AG Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Novartis AG Spinal Muscular Atrophy Medicine Product Portfolio Table 22. Novartis AG Recent Developments Table 23. Astellas Pharma Inc. Company Information Table 24. Astellas Pharma Inc. Business Overview Table 25. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 27. Astellas Pharma Inc. Recent Developments Table 28. WAVE Life Sciences Ltd. Company Information Table 29. WAVE Life Sciences Ltd. Business Overview Table 30. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Portfolio Table 32. WAVE Life Sciences Ltd. Recent Developments Table 33. Vybion, Inc. Company Information Table 34. Vybion, Inc. Business Overview Table 35. Vybion, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Vybion, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 37. Vybion, Inc. Recent Developments Table 38. Voyager Therapeutics, Inc. Company Information Table 39. Voyager Therapeutics, Inc. Business Overview Table 40. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 42. Voyager Therapeutics, Inc. Recent Developments Table 43. Sarepta Therapeutics, Inc. Company Information Table 44. Sarepta Therapeutics, Inc. Business Overview Table 45. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 47. Sarepta Therapeutics, Inc. Recent Developments Table 48. Neurotune AG Company Information Table 49. Neurotune AG Business Overview Table 50. Neurotune AG Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Neurotune AG Spinal Muscular Atrophy Medicine Product Portfolio Table 52. Neurotune AG Recent Developments Table 53. Neurodyn Inc. Company Information Table 54. Neurodyn Inc. Business Overview Table 55. Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 57. Neurodyn Inc. Recent Developments Table 58. Longevity Biotech, Inc Company Information Table 59. Longevity Biotech, Inc Business Overview Table 60. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Portfolio Table 62. Longevity Biotech, Inc Recent Developments Table 63. Ionis Pharmaceuticals, Inc. Company Information Table 64. Ionis Pharmaceuticals, Inc. Business Overview Table 65. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 67. Ionis Pharmaceuticals, Inc. Recent Developments Table 68. GMP-Orphan SAS Company Information Table 69. GMP-Orphan SAS Business Overview Table 70. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Portfolio Table 72. GMP-Orphan SAS Recent Developments Table 73. Genzyme Corporation Company Information Table 74. Genzyme Corporation Business Overview Table 75. Genzyme Corporation Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Genzyme Corporation Spinal Muscular Atrophy Medicine Product Portfolio Table 77. Genzyme Corporation Recent Developments Table 78. Genethon Company Information Table 79. Genethon Business Overview Table 80. Genethon Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Genethon Spinal Muscular Atrophy Medicine Product Portfolio Table 82. Genethon Recent Developments Table 83. F. Hoffmann-La Roche Ltd. Company Information Table 84. F. Hoffmann-La Roche Ltd. Business Overview Table 85. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Portfolio Table 87. F. Hoffmann-La Roche Ltd. Recent Developments Table 88. Cytokinetics, Inc. 24 Company Information Table 89. Cytokinetics, Inc. 24 Business Overview Table 90. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Portfolio Table 92. Cytokinetics, Inc. 24 Recent Developments Table 93. Bioblast Pharma Ltd. Company Information Table 94. Bioblast Pharma Ltd. Business Overview Table 95. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Portfolio Table 97. Bioblast Pharma Ltd. Recent Developments Table 98. AveXis, Inc. Company Information Table 99. AveXis, Inc. Business Overview Table 100. AveXis, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. AveXis, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 102. AveXis, Inc. Recent Developments Table 103. Global Spinal Muscular Atrophy Medicine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 104. Global Spinal Muscular Atrophy Medicine Sales by Region (2021-2026) & (W Units) Table 105. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2021-2026) Table 106. Global Spinal Muscular Atrophy Medicine Sales by Region (2027-2032) & (W Units) Table 107. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2027-2032) Table 108. Global Spinal Muscular Atrophy Medicine Revenue by Region (2021-2026) & (US$ Million) Table 109. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2021-2026) Table 110. Global Spinal Muscular Atrophy Medicine Revenue by Region (2027-2032) & (US$ Million) Table 111. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2027-2032) Table 112. North America Spinal Muscular Atrophy Medicine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. North America Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (W Units) Table 114. North America Spinal Muscular Atrophy Medicine Sales by Country (2027-2032) & (W Units) Table 115. North America Spinal Muscular Atrophy Medicine Revenue by Country (2021-2026) & (US$ Million) Table 116. North America Spinal Muscular Atrophy Medicine Revenue by Country (2027-2032) & (US$ Million) Table 117. Europe Spinal Muscular Atrophy Medicine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Europe Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (W Units) Table 119. Europe Spinal Muscular Atrophy Medicine Sales by Country (2027-2032) & (W Units) Table 120. Europe Spinal Muscular Atrophy Medicine Revenue by Country (2021-2026) & (US$ Million) Table 121. Europe Spinal Muscular Atrophy Medicine Revenue by Country (2027-2032) & (US$ Million) Table 122. Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Asia Pacific Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (W Units) Table 124. Asia Pacific Spinal Muscular Atrophy Medicine Sales by Country (2027-2032) & (W Units) Table 125. Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Country (2021-2026) & (US$ Million) Table 126. Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Country (2027-2032) & (US$ Million) Table 127. South America Spinal Muscular Atrophy Medicine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. South America Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (W Units) Table 129. South America Spinal Muscular Atrophy Medicine Sales by Country (2027-2032) & (W Units) Table 130. South America Spinal Muscular Atrophy Medicine Revenue by Country (2021-2026) & (US$ Million) Table 131. South America Spinal Muscular Atrophy Medicine Revenue by Country (2027-2032) & (US$ Million) Table 132. Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (W Units) Table 134. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country (2027-2032) & (W Units) Table 135. Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Country (2021-2026) & (US$ Million) Table 136. Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Country (2027-2032) & (US$ Million) Table 137. Global Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (W Units) Table 138. Global Spinal Muscular Atrophy Medicine Sales by Type (2027-2032) & (W Units) Table 139. Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2021-2026) Table 140. Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2027-2032) Table 141. Global Spinal Muscular Atrophy Medicine Revenue by Type (2021-2026) & (US$ Million) Table 142. Global Spinal Muscular Atrophy Medicine Revenue by Type (2027-2032) & (US$ Million) Table 143. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2021-2026) Table 144. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2027-2032) Table 145. Global Spinal Muscular Atrophy Medicine Price by Type (2021-2026) & (US$/Unit) Table 146. Global Spinal Muscular Atrophy Medicine Price by Type (2027-2032) & (US$/Unit) Table 147. Global Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (W Units) Table 148. Global Spinal Muscular Atrophy Medicine Sales by Application (2027-2032) & (W Units) Table 149. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2021-2026) Table 150. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2027-2032) Table 151. Global Spinal Muscular Atrophy Medicine Revenue by Application (2021-2026) & (US$ Million) Table 152. Global Spinal Muscular Atrophy Medicine Revenue by Application (2027-2032) & (US$ Million) Table 153. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2021-2026) Table 154. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2027-2032) Table 155. Global Spinal Muscular Atrophy Medicine Price by Application (2021-2026) & (US$/Unit) Table 156. Global Spinal Muscular Atrophy Medicine Price by Application (2027-2032) & (US$/Unit) Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. Spinal Muscular Atrophy Medicine Distributors List Table 160. Spinal Muscular Atrophy Medicine Customers List Table 161. Spinal Muscular Atrophy Medicine Industry Trends Table 162. Spinal Muscular Atrophy Medicine Industry Drivers Table 163. Spinal Muscular Atrophy Medicine Industry Restraints Table 164. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Spinal Muscular Atrophy Medicine Product Image Figure 5. Global Spinal Muscular Atrophy Medicine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Spinal Muscular Atrophy Medicine Market Size (2021-2032) & (US$ Million) Figure 7. Global Spinal Muscular Atrophy Medicine Sales (2021-2032) & (W Units) Figure 8. Global Spinal Muscular Atrophy Medicine Average Price (US$/Unit) & (2021-2032) Figure 9. LMI-070 Product Image Figure 10. ND-602 Product Image Figure 11. NT-1654 Product Image Figure 12. NXD-30001 Product Image Figure 13. Nusinersen Product Image Figure 14. Others Product Image Figure 15. Hospital Product Image Figure 16. Clinic Product Image Figure 17. Others Product Image Figure 18. Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers in 2025 Figure 19. Global Manufacturers of Spinal Muscular Atrophy Medicine, Manufacturing Sites & Headquarters Figure 20. Global Top 5 and 10 Spinal Muscular Atrophy Medicine Players Market Share by Revenue in 2025 Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Spinal Muscular Atrophy Medicine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 23. Global Spinal Muscular Atrophy Medicine Sales by Region in 2025 Figure 24. Global Spinal Muscular Atrophy Medicine Revenue by Region in 2025 Figure 25. North America Spinal Muscular Atrophy Medicine Market Size by Country in 2025 Figure 26. North America Spinal Muscular Atrophy Medicine Sales Market Share by Country (2021-2032) Figure 27. North America Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2021-2032) Figure 28. United States Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Canada Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Spinal Muscular Atrophy Medicine Market Size by Country in 2025 Figure 31. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Country (2021-2032) Figure 32. Europe Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2021-2032) Figure 33. Germany Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific Spinal Muscular Atrophy Medicine Market Size by Country in 2025 Figure 44. Asia Pacific Spinal Muscular Atrophy Medicine Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2021-2032) Figure 46. China Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America Spinal Muscular Atrophy Medicine Market Size by Country in 2025 Figure 55. South America Spinal Muscular Atrophy Medicine Sales Market Share by Country (2021-2032) Figure 56. South America Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2021-2032) Figure 57. Brazil Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Middle East and Africa Spinal Muscular Atrophy Medicine Market Size by Country in 2025 Figure 61. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Market Share by Country (2021-2032) Figure 62. Middle East and Africa Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2021-2032) Figure 63. Egypt Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. South Africa Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Israel Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Türkiye Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. GCC Countries Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2021-2032) Figure 69. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2021-2032) Figure 70. Global Spinal Muscular Atrophy Medicine Price (US$/Unit) by Type (2021-2032) Figure 71. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2021-2032) Figure 72. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2021-2032) Figure 73. Global Spinal Muscular Atrophy Medicine Price (US$/Unit) by Application (2021-2032) Figure 74. Spinal Muscular Atrophy Medicine Value Chain Figure 75. Spinal Muscular Atrophy Medicine Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Spinal Muscular Atrophy Medicine Industry Opportunities and Challenges

Scope & coverage.

Types
  • LMI-070
  • ND-602
  • NT-1654
  • NXD-30001
  • Nusinersen
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis AG
  • Astellas Pharma Inc.
  • WAVE Life Sciences Ltd.
  • Vybion, Inc.
  • Voyager Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Neurotune AG
  • Neurodyn Inc.
  • Longevity Biotech, Inc
  • Ionis Pharmaceuticals, Inc.
  • GMP-Orphan SAS
  • Genzyme Corporation
  • Genethon
  • F. Hoffmann-La Roche Ltd.
  • Cytokinetics, Inc. 24
  • Bioblast Pharma Ltd.
  • AveXis, Inc.

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Spinal Muscular Atrophy Medicine Market Size (2021-2032)
  4. 2.2.2 Global Spinal Muscular Atrophy Medicine Sales (2021-2032)
  5. 2.2.3 Global Spinal Muscular Atrophy Medicine Market Average Price (2021-2032)
  6. 2.3 Spinal Muscular Atrophy Medicine by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 LMI-070
  9. 2.3.3 ND-602
  10. 2.3.4 NT-1654
  11. 2.3.5 NXD-30001
  12. 2.3.6 Nusinersen
  13. 2.3.7 Others
  14. 2.4 Spinal Muscular Atrophy Medicine by Application
  15. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  16. 2.4.2 Hospital
  17. 2.4.3 Clinic
  18. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Spinal Muscular Atrophy Medicine Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Spinal Muscular Atrophy Medicine Sales (W Units) of Manufacturers (2021-2026)
  3. 3.3 Global Spinal Muscular Atrophy Medicine Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Spinal Muscular Atrophy Medicine Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Spinal Muscular Atrophy Medicine Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Spinal Muscular Atrophy Medicine, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Spinal Muscular Atrophy Medicine, Product Type & Application
  8. 3.8 Global Manufacturers of Spinal Muscular Atrophy Medicine, Established Date
  9. 3.9 Global Spinal Muscular Atrophy Medicine Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Novartis AG
  2. 4.1.1 Novartis AG Company Information
  3. 4.1.2 Novartis AG Business Overview
  4. 4.1.3 Novartis AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Novartis AG Spinal Muscular Atrophy Medicine Product Portfolio
  6. 4.1.5 Novartis AG Recent Developments
  7. 4.2 Astellas Pharma Inc.
  8. 4.2.1 Astellas Pharma Inc. Company Information
  9. 4.2.2 Astellas Pharma Inc. Business Overview
  10. 4.2.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  12. 4.2.5 Astellas Pharma Inc. Recent Developments
  13. 4.3 WAVE Life Sciences Ltd.
  14. 4.3.1 WAVE Life Sciences Ltd. Company Information
  15. 4.3.2 WAVE Life Sciences Ltd. Business Overview
  16. 4.3.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Portfolio
  18. 4.3.5 WAVE Life Sciences Ltd. Recent Developments
  19. 4.4 Vybion, Inc.
  20. 4.4.1 Vybion, Inc. Company Information
  21. 4.4.2 Vybion, Inc. Business Overview
  22. 4.4.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Vybion, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  24. 4.4.5 Vybion, Inc. Recent Developments
  25. 4.5 Voyager Therapeutics, Inc.
  26. 4.5.1 Voyager Therapeutics, Inc. Company Information
  27. 4.5.2 Voyager Therapeutics, Inc. Business Overview
  28. 4.5.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  30. 4.5.5 Voyager Therapeutics, Inc. Recent Developments
  31. 4.6 Sarepta Therapeutics, Inc.
  32. 4.6.1 Sarepta Therapeutics, Inc. Company Information
  33. 4.6.2 Sarepta Therapeutics, Inc. Business Overview
  34. 4.6.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  36. 4.6.5 Sarepta Therapeutics, Inc. Recent Developments
  37. 4.7 Neurotune AG
  38. 4.7.1 Neurotune AG Company Information
  39. 4.7.2 Neurotune AG Business Overview
  40. 4.7.3 Neurotune AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Neurotune AG Spinal Muscular Atrophy Medicine Product Portfolio
  42. 4.7.5 Neurotune AG Recent Developments
  43. 4.8 Neurodyn Inc.
  44. 4.8.1 Neurodyn Inc. Company Information
  45. 4.8.2 Neurodyn Inc. Business Overview
  46. 4.8.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  48. 4.8.5 Neurodyn Inc. Recent Developments
  49. 4.9 Longevity Biotech, Inc
  50. 4.9.1 Longevity Biotech, Inc Company Information
  51. 4.9.2 Longevity Biotech, Inc Business Overview
  52. 4.9.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Portfolio
  54. 4.9.5 Longevity Biotech, Inc Recent Developments
  55. 4.10 Ionis Pharmaceuticals, Inc.
  56. 4.10.1 Ionis Pharmaceuticals, Inc. Company Information
  57. 4.10.2 Ionis Pharmaceuticals, Inc. Business Overview
  58. 4.10.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  60. 4.10.5 Ionis Pharmaceuticals, Inc. Recent Developments
  61. 4.11 GMP-Orphan SAS
  62. 4.11.1 GMP-Orphan SAS Company Information
  63. 4.11.2 GMP-Orphan SAS Business Overview
  64. 4.11.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Portfolio
  66. 4.11.5 GMP-Orphan SAS Recent Developments
  67. 4.12 Genzyme Corporation
  68. 4.12.1 Genzyme Corporation Company Information
  69. 4.12.2 Genzyme Corporation Business Overview
  70. 4.12.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Genzyme Corporation Spinal Muscular Atrophy Medicine Product Portfolio
  72. 4.12.5 Genzyme Corporation Recent Developments
  73. 4.13 Genethon
  74. 4.13.1 Genethon Company Information
  75. 4.13.2 Genethon Business Overview
  76. 4.13.3 Genethon Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Genethon Spinal Muscular Atrophy Medicine Product Portfolio
  78. 4.13.5 Genethon Recent Developments
  79. 4.14 F. Hoffmann-La Roche Ltd.
  80. 4.14.1 F. Hoffmann-La Roche Ltd. Company Information
  81. 4.14.2 F. Hoffmann-La Roche Ltd. Business Overview
  82. 4.14.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Portfolio
  84. 4.14.5 F. Hoffmann-La Roche Ltd. Recent Developments
  85. 4.15 Cytokinetics, Inc. 24
  86. 4.15.1 Cytokinetics, Inc. 24 Company Information
  87. 4.15.2 Cytokinetics, Inc. 24 Business Overview
  88. 4.15.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Portfolio
  90. 4.15.5 Cytokinetics, Inc. 24 Recent Developments
  91. 4.16 Bioblast Pharma Ltd.
  92. 4.16.1 Bioblast Pharma Ltd. Company Information
  93. 4.16.2 Bioblast Pharma Ltd. Business Overview
  94. 4.16.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Portfolio
  96. 4.16.5 Bioblast Pharma Ltd. Recent Developments
  97. 4.17 AveXis, Inc.
  98. 4.17.1 AveXis, Inc. Company Information
  99. 4.17.2 AveXis, Inc. Business Overview
  100. 4.17.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 AveXis, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  102. 4.17.5 AveXis, Inc. Recent Developments
5 Global Spinal Muscular Atrophy Medicine Market Scenario by Region
  1. 5.1 Global Spinal Muscular Atrophy Medicine Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Spinal Muscular Atrophy Medicine Sales by Region: 2021-2032
  3. 5.2.1 Global Spinal Muscular Atrophy Medicine Sales by Region: 2021-2026
  4. 5.2.2 Global Spinal Muscular Atrophy Medicine Sales by Region: 2027-2032
  5. 5.3 Global Spinal Muscular Atrophy Medicine Revenue by Region: 2021-2032
  6. 5.3.1 Global Spinal Muscular Atrophy Medicine Revenue by Region: 2021-2026
  7. 5.3.2 Global Spinal Muscular Atrophy Medicine Revenue by Region: 2027-2032
  8. 5.4 North America Spinal Muscular Atrophy Medicine Market Facts & Figures by Country
  9. 5.4.1 North America Spinal Muscular Atrophy Medicine Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Spinal Muscular Atrophy Medicine Sales by Country (2021-2032)
  11. 5.4.3 North America Spinal Muscular Atrophy Medicine Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Spinal Muscular Atrophy Medicine Market Facts & Figures by Country
  15. 5.5.1 Europe Spinal Muscular Atrophy Medicine Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Spinal Muscular Atrophy Medicine Sales by Country (2021-2032)
  17. 5.5.3 Europe Spinal Muscular Atrophy Medicine Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Russia
  23. 5.5.9 Spain
  24. 5.5.10 Netherlands
  25. 5.5.11 Switzerland
  26. 5.5.12 Sweden
  27. 5.5.13 Poland
  28. 5.6 Asia Pacific Spinal Muscular Atrophy Medicine Market Facts & Figures by Country
  29. 5.6.1 Asia Pacific Spinal Muscular Atrophy Medicine Market Size by Country: 2021 VS 2025 VS 2032
  30. 5.6.2 Asia Pacific Spinal Muscular Atrophy Medicine Sales by Country (2021-2032)
  31. 5.6.3 Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Country (2021-2032)
  32. 5.6.4 China
  33. 5.6.5 Japan
  34. 5.6.6 South Korea
  35. 5.6.7 India
  36. 5.6.8 Australia
  37. 5.6.9 Taiwan
  38. 5.6.10 Southeast Asia
  39. 5.7 South America Spinal Muscular Atrophy Medicine Market Facts & Figures by Country
  40. 5.7.1 South America Spinal Muscular Atrophy Medicine Market Size by Country: 2021 VS 2025 VS 2032
  41. 5.7.2 South America Spinal Muscular Atrophy Medicine Sales by Country (2021-2032)
  42. 5.7.3 South America Spinal Muscular Atrophy Medicine Revenue by Country (2021-2032)
  43. 5.7.4 Brazil
  44. 5.7.5 Argentina
  45. 5.7.6 Chile
  46. 5.8 Middle East and Africa Spinal Muscular Atrophy Medicine Market Facts & Figures by Country
  47. 5.8.1 Middle East and Africa Spinal Muscular Atrophy Medicine Market Size by Country: 2021 VS 2025 VS 2032
  48. 5.8.2 Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country (2021-2032)
  49. 5.8.3 Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Country (2021-2032)
  50. 5.8.4 Egypt
  51. 5.8.5 South Africa
  52. 5.8.6 Israel
  53. 5.8.7 Türkiye
  54. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Spinal Muscular Atrophy Medicine Sales by Type (2021-2032)
  2. 6.1.1 Global Spinal Muscular Atrophy Medicine Sales by Type (2021-2032) & (W Units)
  3. 6.1.2 Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2021-2032)
  4. 6.2 Global Spinal Muscular Atrophy Medicine Revenue by Type (2021-2032)
  5. 6.2.1 Global Spinal Muscular Atrophy Medicine Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Spinal Muscular Atrophy Medicine Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Spinal Muscular Atrophy Medicine Sales by Application (2021-2032)
  2. 7.1.1 Global Spinal Muscular Atrophy Medicine Sales by Application (2021-2032) & (W Units)
  3. 7.1.2 Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2021-2032)
  4. 7.2 Global Spinal Muscular Atrophy Medicine Revenue by Application (2021-2032)
  5. 7.2.1 Global Spinal Muscular Atrophy Medicine Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Spinal Muscular Atrophy Medicine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Spinal Muscular Atrophy Medicine Value Chain Analysis
  2. 8.1.1 Spinal Muscular Atrophy Medicine Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Spinal Muscular Atrophy Medicine Production Mode & Process
  5. 8.2 Spinal Muscular Atrophy Medicine Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Spinal Muscular Atrophy Medicine Distributors
  8. 8.2.3 Spinal Muscular Atrophy Medicine Customers
9 Global Spinal Muscular Atrophy Medicine Analyzing Market Dynamics
  1. 9.1 Spinal Muscular Atrophy Medicine Industry Trends
  2. 9.2 Spinal Muscular Atrophy Medicine Industry Drivers
  3. 9.3 Spinal Muscular Atrophy Medicine Industry Opportunities and Challenges
  4. 9.4 Spinal Muscular Atrophy Medicine Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst